Health Problems of Civilization
eISSN: 2354-0265
ISSN: 2353-6942
Health Problems of Civilization Physical activity: diseases and issues recognized by the WHO
Bieżący numer Archiwum Online first O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
Poleć ten artykuł:
Udostępnij:
Opis przypadku

FUNGAL COMPLICATIONS IN A PATIENT UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

Filip Przemysław Krzanowski
1
,
Anna Halot
1
,
Małgorzata Kozioł
2
,
Jacek Krzanowski
3

  1. Students Scientific Association at the Chair and Department of Medical Microbiology, Medical University of Lublin, Poland
  2. Department of Medical Microbiology, Medical University of Lublin, Poland
  3. Department of Hematology-Oncology, Specialist Hospital in Brzozow, Poland
Health Problems of Civilization
Data publikacji online: 2025/05/19
Plik artykułu:
- Krzanowski et al.pdf  [0.39 MB]
Pobierz cytowanie
 
Metryki PlumX:
 
1. Zhou S, Aitken SL. Prophylaxis against Pneumocystis jirovecii pneumonia in adults. JAMA. 2023; 330(2): 182-3.
2. Coda JE, Raser K, Anand SM, Ghosh M, Maciejewski J, Pawarode A, et al. Pneumocystis jirovecii infection in autologous hematopoietic stem cell transplant recipients. Blood. 2021; 138(Suppl 1): 4898. https://doi.org/10.1182/blood-2021-144633
3. Stavi V, Desai N, Michelis FV, Kim DDH, Kumar R, Lipton JH, et al. Late-onset Pneumocystis jirovecii pneumonia post-allogeneic stem cell transplantation: a retrospective study. Eur J Haematol. 2023; 110(6): 573-80.
4. McCollam S, Lewis JS, Bubalo J, Diaz A. Pneumocystis jirovecii pneumonia prophylaxis with intravenous pentamidine in allogeneic hematopoietic stem cell transplant recipients. Antimicrob Agents Chemother. 2022; 66(10): e00833-22. https://doi.org/10.1128/aac.00833-22
5. Haseeb A, Abourehab MAS, Almalki WA, Almontashri AM, Bajawi SA, Aljoaid AM, et al. Trimethoprim-Sulfamethoxazole dose optimization in Pneumocystis jirovecii pneumonia management: a systematic review. Int J Environ Res Public Health. 2022; 19(5): 2833. https://doi.org/10.3390/ijerph19052833
6. Li Y, Liu H, Lv Q, Long J. Diagnosis model of early Pneumocystis jirovecii pneumonia based on convolutional neural network: a comparison with traditional PCR diagnostic method. BMC Pulm Med. 2024; 24: 205. https://doi.org/10.1186/s12890-024-02987-x
7. Chen RY, Li DW, Wang JY, Zhuang SY, Wu HY, Wu JJ, et al. Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in kidney transplant recipients. Transpl Infect Dis. 2022; 24(6): e13908. https://doi.org/10.1111/tid.13908
8. Alshahrani MY, Alfaifi M, Ahmad I, Alatawi RA, Alzahrani M, Alqurashi M, et al. Pneumocystis jirovecii detection and comparison of multiple diagnostic methods with quantitative real-time PCR in patients with respiratory symptoms. Saudi J Biol Sci. 2020; 27(6): 1423-7. https://doi.org/10.1016/j.sjbs.2020.04.032
9. Hsu JM, Hass A, Gingras MA, Avila JL, Tran TD, Chen S, et al. Radiographic features in patients investigated for Pneumocystis jirovecii pneumonia: a nested case-control study. BMC Infect Dis. 2020; 20(1): 492. https://doi.org/10.1186/s12879-020-05217-x
10. Nagai T, Matsui H, Fujioka H, Homma Y, Otsuki A, Ito H, et al. Low-dose vs conventional-dose Trimethoprim-Sulfamethoxazole for treatment of Pneumocystis jirovecii pneumonia. Chest. 2023; 164(2): 312-9. https://doi.org/10.1016/j.chest.2023.05.026
11. Masaki T, Ishikawa K, Fujino T, Koyamada R, Kawai F, Ota E, et al. Intermittent versus daily Trimethoprim/Sulfamethoxazole regimens for Pneumocystis pneumonia prophylaxis: a systematic review and meta-analysis. Open Forum Infect Dis. 2022; 9(4): ofae499. https://doi.org/10.1093/ofid/ofae499
Copyright: © 2025 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

© 2025 Termedia Sp. z o.o.
Developed by Bentus.

Nowe wytyczne dla autorów!

Od 1 stycznia 2025 roku, wszyscy autorzy są zobowiązani do przestrzegania nowych wytycznych dotyczących publikacji w „Health Problems of Civilization”.

Przygotowując artykuł do złożenia w czasopiśmie, Autorzy muszą postępować zgodnie z instrukcjami formatowania zawartymi w szablonach Word, które można znaleźć w sekcji "Zasady publikacji prac" na naszej stronie internetowej.

Nowe informacje o opłatach!